Cicada Surge: Vaccines Still Shield Against BA.3.2 Despite Heavy Mutations

The BA.3.2 “Cicada” variant, a sub-lineage of Omicron, has been detected across multiple countries, including the US and South Africa. Despite its high mutation count, doctors and researchers emphasize that vaccines still provide strong protection against severe outcomes, even if breakthrough infections occur.

Variant Characteristics

BA.3.2 carries 70–75 mutations, particularly in the spike protein, which may reduce antibody neutralization. Symptoms largely mirror earlier Covid strains: fever, cough, sore throat, fatigue, and body aches. Severity remains low compared to Delta, with most cases presenting mild to moderate illness.

Vaccine Effectiveness

Current vaccines, including updated 2025–26 formulations, continue to protect against severe illness. Experts recommend booster doses to strengthen immunity, especially for high-risk groups such as the elderly and those with comorbidities. Vaccination remains the most effective tool to prevent hospitalization and death.

Key Highlights

•⁠  ⁠Cicada BA.3.2 variant carries 70+ mutations

•⁠  ⁠Symptoms similar to earlier Covid strains, mostly mild

•⁠  ⁠Vaccines remain effective against severe illness and death

•⁠  ⁠Booster doses recommended for stronger immunity

•⁠  ⁠WHO classifies BA.3.2 as Variant Under Monitoring

What It Means For Public Health

The emergence of BA.3.2 underscores the importance of continued vaccination, boosters, and adherence to precautions. While the variant spreads rapidly, experts advise against panic, stressing that vaccines and vigilance remain the best defense against evolving Covid threats.

Sources: Times Now, News9Live, India TV